Cargando…

Chlamydiaphage φCPG1 Capsid Protein Vp1 Inhibits Chlamydia trachomatis Growth via the Mitogen-Activated Protein Kinase Pathway

Chlamydia trachomatis is the most common cause of curable bacterial sexually transmitted infections worldwide. Although the pathogen is well established, the pathogenic mechanisms remain unclear. Given the current challenges of antibiotic resistance and blocked processes of vaccine development, the...

Descripción completa

Detalles Bibliográficos
Autores principales: Guo, Yuanli, Guo, Rui, Zhou, Quan, Sun, Changgui, Zhang, Xinmei, Liu, Yuanjun, Liu, Quanzhong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4848593/
https://www.ncbi.nlm.nih.gov/pubmed/27089359
http://dx.doi.org/10.3390/v8040099
_version_ 1782429375574048768
author Guo, Yuanli
Guo, Rui
Zhou, Quan
Sun, Changgui
Zhang, Xinmei
Liu, Yuanjun
Liu, Quanzhong
author_facet Guo, Yuanli
Guo, Rui
Zhou, Quan
Sun, Changgui
Zhang, Xinmei
Liu, Yuanjun
Liu, Quanzhong
author_sort Guo, Yuanli
collection PubMed
description Chlamydia trachomatis is the most common cause of curable bacterial sexually transmitted infections worldwide. Although the pathogen is well established, the pathogenic mechanisms remain unclear. Given the current challenges of antibiotic resistance and blocked processes of vaccine development, the use of a specific chlamydiaphage may be a new treatment solution. φCPG1 is a lytic phage specific for Chlamydia caviae, and shows over 90% nucleotide sequence identity with other chlamydiaphages. Vp1 is the major capsid protein of φCPG1. Purified Vp1 was previously confirmed to inhibit Chlamydia trachomatis growth. We here report the first attempt at exploring the relationship between Vp1-treated C. trachomatis and the protein and gene levels of the mitogen-activated/extracellular regulated protein kinase (MAPK/ERK) pathway by Western blotting and real-time PCR, respectively. Moreover, we evaluated the levels of pro-inflammatory cytokines interleukin (IL)-8 and IL-1 by enzyme-linked immunosorbent assay after Vp1 treatment. After 48 h of incubation, the p-ERK level of the Vp1-treated group decreased compared with that of the Chlamydia infection group. Accordingly, ERK1 and ERK2 mRNA expression levels of the Vp1-treated group also decreased compared with the Chlamydia infection group. IL-8 and IL-1 levels were also decreased after Vp1 treatment compared with the untreated group. Our results demonstrate that the inhibition effect of the chlamydiaphage φCPG1 capsid protein Vp1 on C. trachomatis is associated with the MAPK pathway, and inhibits production of the pro-inflammatory cytokines IL-8 and IL-1. The bacteriophages may provide insight into a new signaling transduction mechanism to influence their hosts, in addition to bacteriolysis.
format Online
Article
Text
id pubmed-4848593
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-48485932016-05-04 Chlamydiaphage φCPG1 Capsid Protein Vp1 Inhibits Chlamydia trachomatis Growth via the Mitogen-Activated Protein Kinase Pathway Guo, Yuanli Guo, Rui Zhou, Quan Sun, Changgui Zhang, Xinmei Liu, Yuanjun Liu, Quanzhong Viruses Article Chlamydia trachomatis is the most common cause of curable bacterial sexually transmitted infections worldwide. Although the pathogen is well established, the pathogenic mechanisms remain unclear. Given the current challenges of antibiotic resistance and blocked processes of vaccine development, the use of a specific chlamydiaphage may be a new treatment solution. φCPG1 is a lytic phage specific for Chlamydia caviae, and shows over 90% nucleotide sequence identity with other chlamydiaphages. Vp1 is the major capsid protein of φCPG1. Purified Vp1 was previously confirmed to inhibit Chlamydia trachomatis growth. We here report the first attempt at exploring the relationship between Vp1-treated C. trachomatis and the protein and gene levels of the mitogen-activated/extracellular regulated protein kinase (MAPK/ERK) pathway by Western blotting and real-time PCR, respectively. Moreover, we evaluated the levels of pro-inflammatory cytokines interleukin (IL)-8 and IL-1 by enzyme-linked immunosorbent assay after Vp1 treatment. After 48 h of incubation, the p-ERK level of the Vp1-treated group decreased compared with that of the Chlamydia infection group. Accordingly, ERK1 and ERK2 mRNA expression levels of the Vp1-treated group also decreased compared with the Chlamydia infection group. IL-8 and IL-1 levels were also decreased after Vp1 treatment compared with the untreated group. Our results demonstrate that the inhibition effect of the chlamydiaphage φCPG1 capsid protein Vp1 on C. trachomatis is associated with the MAPK pathway, and inhibits production of the pro-inflammatory cytokines IL-8 and IL-1. The bacteriophages may provide insight into a new signaling transduction mechanism to influence their hosts, in addition to bacteriolysis. MDPI 2016-04-14 /pmc/articles/PMC4848593/ /pubmed/27089359 http://dx.doi.org/10.3390/v8040099 Text en © 2016 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons by Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Guo, Yuanli
Guo, Rui
Zhou, Quan
Sun, Changgui
Zhang, Xinmei
Liu, Yuanjun
Liu, Quanzhong
Chlamydiaphage φCPG1 Capsid Protein Vp1 Inhibits Chlamydia trachomatis Growth via the Mitogen-Activated Protein Kinase Pathway
title Chlamydiaphage φCPG1 Capsid Protein Vp1 Inhibits Chlamydia trachomatis Growth via the Mitogen-Activated Protein Kinase Pathway
title_full Chlamydiaphage φCPG1 Capsid Protein Vp1 Inhibits Chlamydia trachomatis Growth via the Mitogen-Activated Protein Kinase Pathway
title_fullStr Chlamydiaphage φCPG1 Capsid Protein Vp1 Inhibits Chlamydia trachomatis Growth via the Mitogen-Activated Protein Kinase Pathway
title_full_unstemmed Chlamydiaphage φCPG1 Capsid Protein Vp1 Inhibits Chlamydia trachomatis Growth via the Mitogen-Activated Protein Kinase Pathway
title_short Chlamydiaphage φCPG1 Capsid Protein Vp1 Inhibits Chlamydia trachomatis Growth via the Mitogen-Activated Protein Kinase Pathway
title_sort chlamydiaphage φcpg1 capsid protein vp1 inhibits chlamydia trachomatis growth via the mitogen-activated protein kinase pathway
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4848593/
https://www.ncbi.nlm.nih.gov/pubmed/27089359
http://dx.doi.org/10.3390/v8040099
work_keys_str_mv AT guoyuanli chlamydiaphagephcpg1capsidproteinvp1inhibitschlamydiatrachomatisgrowthviathemitogenactivatedproteinkinasepathway
AT guorui chlamydiaphagephcpg1capsidproteinvp1inhibitschlamydiatrachomatisgrowthviathemitogenactivatedproteinkinasepathway
AT zhouquan chlamydiaphagephcpg1capsidproteinvp1inhibitschlamydiatrachomatisgrowthviathemitogenactivatedproteinkinasepathway
AT sunchanggui chlamydiaphagephcpg1capsidproteinvp1inhibitschlamydiatrachomatisgrowthviathemitogenactivatedproteinkinasepathway
AT zhangxinmei chlamydiaphagephcpg1capsidproteinvp1inhibitschlamydiatrachomatisgrowthviathemitogenactivatedproteinkinasepathway
AT liuyuanjun chlamydiaphagephcpg1capsidproteinvp1inhibitschlamydiatrachomatisgrowthviathemitogenactivatedproteinkinasepathway
AT liuquanzhong chlamydiaphagephcpg1capsidproteinvp1inhibitschlamydiatrachomatisgrowthviathemitogenactivatedproteinkinasepathway